Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 2 (2005), Issue 2 (February)

1. Preoperative sonographic features of borderline ovarian tumors.
   Ultrasound Obstet Gynecol, 25(1): 50-9. [Abstract] [Full-text]
2. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
   Oncogene, 24(6): 1053-65. [Abstract] [Full-text]
3. Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis.
   Am J Epidemiol, 161(4): 321-9. [Abstract] [Full-text]
4. Loss of Gelsolin expression in human ovarian carcinomas.
   Eur J Cancer, 41(3): 461-9. [Abstract] [Full-text]
5. Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells.
   Biochem Biophys Res Commun, 328(2): 567-72. [Abstract] [Full-text]
6. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects.
   Br J Cancer, 92(2): 305-11. [Abstract] [Full-text]
7. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters.
   Br J Cancer, 92(2): 271-7. [Abstract] [Full-text]
8. Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer.
   Br J Cancer, 92(2): 278-83. [Abstract] [Full-text]
9. Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma.
   Br J Cancer, 92(1): 113-9. [Abstract] [Full-text]
10. Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo.
    Br J Cancer, 92(1): 72-9. [Abstract] [Full-text]
11. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.
    J Clin Oncol, 23(5): 973-81. [Abstract] [Full-text]
12. Expression of alpha V-associated integrin beta subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens.
    J Mol Histol, 36(1): 119-29. [Abstract] [Full-text]
13. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study.
    Fertil Steril, 83(2): 284-90; quiz 525-6. [Abstract] [Full-text]
14. Intensity-modulated arc therapy for treatment of high-risk endometrial malignancies.
    Int J Radiat Oncol Biol Phys, 61(3): 830-41. [Abstract] [Full-text]
15. BAG-1 p29 protein prevents drug-induced cell death in the presence of EGF and enhances resistance to anoikis in SKOV3 human ovarian cancer cells.
    Biochem Biophys Res Commun, 328(4): 874-84. [Abstract] [Full-text]
16. Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migration.
    Exp Cell Res, 304(1): 305-16. [Abstract] [Full-text]
17. Bleeding gastric varices--a rare complication of ovarian cancer.
    Int J Clin Pract, 59(1): 119-20. [Abstract] [Full-text]
18. Lysophosphatidic acid inhibits anti-Fas-mediated apoptosis enhanced by actin depolymerization in epithelial ovarian cancer.
    FEBS Lett, 579(5): 1311-9. [Abstract] [Full-text]
19. Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2.
    Int J Cancer, 114(4): 531-43. [Abstract] [Full-text]
20. Lessons from controversy: ovarian cancer screening and serum proteomics.
    J Natl Cancer Inst, 97(4): 315-9. [Abstract] [Full-text]
21. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer.
    J Natl Cancer Inst, 97(4): 307-9. [Abstract] [Full-text]
22. Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions.
    Am J Clin Pathol, 123(3): 360-8. [Abstract] [Full-text]
23. Cytologic scoring of endometrioid adenocarcinoma of the endometrium.
    Cancer, 105(1): 8-12. [Abstract] [Full-text]
24. Distribution of Y-chromosome-bearing cells in gonadoblastoma and dysgenetic testis in 45,X/46,XY infants.
    Mod Pathol, 18(3): 439-45. [Abstract] [Full-text]
25. Relations of gestational length and timing and type of incomplete pregnancy to ovarian cancer risk.
    Am J Epidemiol, 161(5): 452-61. [Abstract] [Full-text]
26. Genetic variation in the progesterone receptor gene and ovarian cancer risk.
    Am J Epidemiol, 161(5): 442-51. [Abstract] [Full-text]
27. Proteome changes in ovarian epithelial cells derived from women with BRCA1 mutations and family histories of cancer.
    Mol Cell Proteomics, 4(2): 156-68. [Abstract] [Full-text]
28. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer.
    Gynecol Oncol, 96(3): 902-5. [Abstract] [Full-text]
29. Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma.
    Gynecol Oncol, 96(3): 888-91. [Abstract] [Full-text]
30. Prolonged survival following salvage surgery for chemorefractory ovarian immature teratoma: a case report and review of the literature.
    Gynecol Oncol, 96(3): 883-7. [Abstract] [Full-text]
31. Leydig cell tumor in an elderly patient with complete androgen insensitivity syndrome.
    Gynecol Oncol, 96(3): 870-2. [Abstract] [Full-text]
32. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature.
    Gynecol Oncol, 96(3): 865-9. [Abstract] [Full-text]
33. Ovarian luteinized thecoma with sclerosing peritonitis in an adult woman treated with leuprolide and toremifene in complete remission at 5 years.
    Gynecol Oncol, 96(3): 846-9. [Abstract] [Full-text]
34. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
    Gynecol Oncol, 96(3): 810-7. [Abstract] [Full-text]
35. Outcome and prognostic factors in ovarian germ cell malignancies.
    Gynecol Oncol, 96(3): 784-91. [Abstract] [Full-text]
36. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study.
    Gynecol Oncol, 96(3): 729-35. [Abstract] [Full-text]
37. Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer.
    Gynecol Oncol, 96(3): 701-4. [Abstract] [Full-text]
38. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
    Gynecol Oncol, 96(3): 684-94. [Abstract] [Full-text]
39. Effects of prolonged tamoxifen treatment on receptor expression and apoptosis of ovarian cancer cells.
    Gynecol Oncol, 96(3): 678-83. [Abstract] [Full-text]
40. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer.
    Gynecol Oncol, 96(3): 671-7. [Abstract] [Full-text]
41. Gene therapy of adenovirus mediated CD ::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer.
    Gynecol Oncol, 96(3): 643-50. [Abstract] [Full-text]
42. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
    Gynecol Oncol, 96(3): 601-9. [Abstract] [Full-text]
43. Laparoscopic management of borderline ovarian tumors: results of a French multicenter study.
    Ann Oncol, 16(3): 403-10. [Abstract] [Full-text]
44. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
    Am J Med Genet A, 133(2): 165-9. [Abstract] [Full-text]
45. Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.
    Semin Oncol, 31(6): 19-24. [Abstract] [Full-text]
46. Location of inclusion cysts in mouse ovaries in relation to age, pregnancy, and total ovulation number: implications for ovarian cancer?
    J Pathol, 205(4): 483-90. [Abstract] [Full-text]
47. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.
    Gene Ther, 12(5): 461-6. [Abstract] [Full-text]
48. The benefit of chemotherapy in a patient with multiple brain metastases and meningitis carcinomatosa from ovarian cancer.
    Int J Clin Oncol, 10(1): 69-71. [Abstract] [Full-text]
49. Stroke as a first manifestation of ovarian cancer.
    J Neurooncol, 71(3): 267-9. [Abstract] [Full-text]
50. The role of CA125 in clinical practice.
    J Clin Pathol, 58(3): 308-12. [Abstract] [Full-text]
51. Plasma bikunin as a favorable prognostic factor in ovarian cancer.
    J Clin Oncol, 23(7): 1463-72. [Abstract] [Full-text]
52. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.
    Cancer Res, 65(4): 1471-8. [Abstract] [Full-text]
53. Distal Chr 4 harbors a genetic locus (Gct1) fundamental for spontaneous ovarian granulosa cell tumorigenesis in a mouse model.
    Cancer Res, 65(4): 1259-64. [Abstract] [Full-text]
54. Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer.
    Cancer Epidemiol Biomarkers Prev, 14(2): 319-23. [Abstract] [Full-text]
55. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Cancer Epidemiol Biomarkers Prev, 14(2): 306-18. [Abstract] [Full-text]
56. Exploratory study of ovarian intraepithelial neoplasia.
    Cancer Epidemiol Biomarkers Prev, 14(2): 299-305. [Abstract] [Full-text]
57. Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors.
    Eur J Obstet Gynecol Reprod Biol, 119(1): 108-13. [Abstract] [Full-text]
58. Serum tumor necrosis factor alpha receptors p55/p75 ratio and ovarian cancer detection.
    Int J Gynaecol Obstet, 88(3): 292-8. [Abstract] [Full-text]
59. Prognostic significance of DNA quantification by flow cytometry in ovarian tumors.
    Int J Gynaecol Obstet, 88(3): 286-91. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.